Invention Grant
US09427455B2 Use of the pat nanopeptide in the treatment of autoimmune diseases
有权
使用pat纳米肽治疗自身免疫性疾病
- Patent Title: Use of the pat nanopeptide in the treatment of autoimmune diseases
- Patent Title (中): 使用pat纳米肽治疗自身免疫性疾病
-
Application No.: US12736599Application Date: 2009-04-15
-
Publication No.: US09427455B2Publication Date: 2016-08-30
- Inventor: Jamal Temsamani , Claude Laruelle
- Applicant: Jamal Temsamani , Claude Laruelle
- Applicant Address: FR Nice
- Assignee: CLL PHARMA
- Current Assignee: CLL PHARMA
- Current Assignee Address: FR Nice
- Agency: Young & Thompson
- Priority: FR0802220 20080421
- International Application: PCT/FR2009/000439 WO 20090415
- International Announcement: WO2009/150310 WO 20091217
- Main IPC: A61K38/00
- IPC: A61K38/00 ; C07K16/00 ; A61K38/08
Abstract:
The invention refers to the use of the PAT nonapeptide which is a thymuline analog in the treatment of autoimmune diseases, in particular of rheumatoid arthritis and intestinal bowel diseases (IBD) such as the Crohn's disease.
Public/Granted literature
- US20110098223A1 USE OF THE PAT NANOPEPTIDE IN THE TREATMENT OF AUTOIMMUNE DISEASES Public/Granted day:2011-04-28
Information query
IPC分类:
